Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer
Alan Sandler, MD
Advertisement
Articles by Alan Sandler, MD
Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action
Advertisement
Latest Updated Articles
Dr. Sandler Discusses the Tivantinib Mechanism of ActionPublished: June 25th 2012 | Updated:
Dr. Sandler on Immunotherapies to Treat Lung CancerPublished: August 2nd 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5